Trial Profile

Prospective Phase I Study of Gax (Gemcitabine, ABRAXANE, and Xeloda) for Metastatic Pancreatic Cancer Protocol # TSH - APG - 2015-01

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 09 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Pancreatic cancer
Focus Adverse reactions

Most Recent Events

05 Dec 2016 Planned End Date changed from 1 Nov 2021 to 1 Dec 2016.
05 Dec 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2016.
05 Dec 2016 Planned initiation date changed from 1 Nov 2015 to 1 Feb 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com